Table 1 Patient characteristics, clinical covariates, and clinical findings stratified by PERT presence and PERT consultation
PERT PRESENT | PERT CONSULTED | |||||
|---|---|---|---|---|---|---|
Pre-PERT: n = 319 patients1 | Post-PERT: n = 367 patients1 | p-value2 | PERT NOT CONSULTED: n = 166 patients1 | PERT CONSULTED: n = 201 patients1 | p-value2 | |
Patient demographics | ||||||
Age (Years) | 62 (52, 73) | 64 (53, 73) | 0.6 | 65 (53, 74) | 63 (53, 72) | 0.4 |
Sex | 0.4 | 0.7 | ||||
Male | 175 (54.9%) | 212 (58%) | 98 (59.0%) | 114 (56.7%) | ||
Female | 144 (45.1%) | 155 (42%) | 68 (41.0%) | 87 (43.3%) | ||
Clinical covariates | ||||||
COPD | 37 (11.6%) | 41 (11.2%) | > 0.9 | 11 (6.6%) | 30 (14.9%) | 0.012* |
Congestive heart failure | 51 (16.0%) | 56 (15.3%) | 0.8 | 33 (19.9%) | 23 (11.4%) | 0.025* |
ILD | 8 (2.5%) | 11 (3.0%) | 0.7 | 8 (4.8%) | 3 (1.5%) | 0.072 |
Pulmonary HTN | 28 (8.8%) | 30 (8.2%) | 0.8 | 11 (6.6%) | 19 (9.5%) | 0.3 |
Active Cancer | 104 (32.6%) | 83 (22.6%) | 0.003* | 48 (28.9%) | 35 (17.4%) | 0.009* |
History of Venous Thromboembolism | 66 (20.7%) | 56 (15.3%) | 0.064 | 19 (11.4%) | 37 (18.4%) | 0.065 |
Cirrhosis | 4 (1.3%) | 7 (1.9%) | 0.5 | 6 (3.6%) | 1 (0.5%) | 0.049* |
History of GI Bleed | 12 (3.8%) | 15 (4.1%) | 0.8 | 7 (4.2%) | 8 (4.0%) | > 0.9 |
History of Thrombophilia | 8 (2.5%) | 9 (2.5%) | > 0.9 | 1 (0.6%) | 8 (4.0%) | 0.044* |
Autoimmune Disease | 47 (14.7%) | 48 (13.1%) | 0.5 | 25 (15.1%) | 23 (11.4%) | 0.3 |
History of COVID-19 | 0 (0%) | 44 (12%) | < 0.001* | 24 (14%) | 20 (10.0%) | 0.3 |
Home anticoagulation | 25 (7.8%) | 14 (3.8%) | 0.023* | 8 (4.8%) | 6 (3.0%) | 0.4 |
Apixaban | 6 (24.0%) | 3 (21.4%) | 2 (25.0%) | 1 (16.7%) | ||
Dabigatran | 1 (4.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | ||
Dalteparin | 2 (8.0%) | 1 (0.0%) | 1 (0.0%) | 0 (0.0%) | ||
Edoxaban | 0 (0.0%) | 2 (7.1%) | 2 (12.5%) 0 | 1 (0.0%) | ||
Enoxaparin | 4 (16.0%) | 1 (7.1%) | (0.0%) | 2 (16.7%) | ||
Rivaroxaban | 5 (20.0%) | 3 (21.4%) | 1 (12.5%) | 3 (33.3%) | ||
Warfarin | 7 (28.0%) | 6 (42.9%) | 4 (50.0%) | 2 (33.3%) | ||
Active Bleed at Diagnosis | 19 (6.0%) | 21 (5.7%) | 0.9 | 15 (9.0%) | 6 (3.0%) | 0.013* |
Presence of PE contributed to admission | 226 (70.8*%) | 270 (73.6%) | 0.5 | 96 (57%) | 175 (87%) | < 0.001 |
Clinical findings | ||||||
Troponin-I | 0.10 (0.02, 0.44) | 0.08 (0.02, 0.3) | 0.3 | 0.07 (0.02, 0.22) | 0.10 (0.03, 0.36) | 0.11 |
BNP | 228 (82, 592) | 201 (71, 559) | 0.3 | 200 (74, 462) | 201 (70, 563) | 0.9 |
Echocardiographic Evidence of RH Strain | 0.2 | < 0.001* | ||||
Yes | 227 (71.2%) | 263 (71.7%) | 97 (58.4%) | 166 (82.6%) | ||
No | 54 (16.9%) | 74 (20.2%) | 40 (24.1%) | 34 (16.9%) | ||
Not Obtained | 38 (11.9%) | 30 (8.2%) | 29 (17.5%) | 1 (0.5%) | ||
CT Evidence of RH Strain | 0.4 | < 0.001* | ||||
Yes | 193 (60.5%) | 221 (60.2%) | 76 (46%) | 145 (72.1%) | ||
No | 111 (34.8%) | 136 (37.1%) | 85 (51%) | 51 (25.4%) | ||
Not Obtained | 15 (4.7%) | 10 (2.7) | 5 (3.0%) | 5 (2.5%) | ||
Full Risk Stratification Obtained (troponin or BNP, plus CT or TTE) | 196 (61.4%) | 277 (75.5%) | < 0.001* | 89 (53.6%) | 188 (93.5%) | < 0.001* |
PE Classification | 0.2 | 0.004* | ||||
High-Risk | 36 (13.2%) | 31 (9.1%) | 12 (8.5%) | 19 (9.6%) | ||
Intermediate-High Risk | 151 (55.3%) | 188 (55%) | 65 (46%) | 123 (62%) | ||
Intermediate-Low Risk | 86 (31.5%) | 121 (36%) | 65 (46%) | 56 (28%) | ||
Not Risk Stratified | 46 (14.4%) | 27 (7.4%) | 24 (14.5%) | 3 (1.5%) | ||
PESI | 106 (83,134) | 105 (82, 138) | 0.7 | 110 (85, 138) | 104 (80, 138) | 0.6 |